Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1

Trial StartFLT201Positive

AI Analysis

Summary

Spur Therapeutics announced the first patient has been dosed in the GALILEO-3 pivotal Phase 3 clinical trial of FLT201 for treating Gaucher Disease Type 1.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in GALILEO-3 pivotal clinical trial

Importance:5/10

Sentiment:

0.40

clinical trialrare diseaseGaucher Diseasepivotal trialFLT201

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 7, 2026 12:00 PM

Read Original